ClinicalTrials.gg
Enrolling by invitationNCT06415110Updated Aug 22, 2025

A Prospective Analysis of the Efficacy of Allosync Expand and Autograft Bone Graft in Open Lumbar Spinal Fusion

An observational study in Spondylolisthesis, Grade 1, sponsored by Research Source. Enrolling by invitation at 1 site in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Research Source · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 102 studies in Spondylolisthesis with a site in United States — 14 open to participants now, 18 under way, none of them phase 3. Spondylolisthesis · United States.

Planned enrollment
28th of 38
40 · median 114
Started
2024
with 4 others
Observational
38 of 102
6 open now
Primary completion
2026-05
later than 3 of 17 live
Registered
98th of 102
by date

Among the 102 studies in Spondylolisthesis with a site in United States, this one is the 28th largest by planned enrollment of the 38 observational ones that give a count, is one of 5 that started in 2024, is one of 38 observational ones, reaches primary completion later than 3 of the 17 other live ones, and was the 98th registered.

Spondylolisthesis

227 studies on the registry are indexed under Spondylolisthesis; 43 are open to participants now.

Browse Spondylolisthesis studies →

Open to participants now

14 of the 102 studies in Spondylolisthesis with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Spondylolisthesis studies recruiting now, 11 (41%) set no upper age limit and 8 (30%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 22 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Spondylolisthesis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the radiographic and clinical outcomes of spinal fusion following use of Allosync Expand and autograft bone graft.

Read the detailed description

This is a single site, prospective study with patients selected as study subjects from the Investigator's standard patient population who fulfill the Inclusion/Exclusion Criteria and agree to participate in the study. The study surgery is standard of care, with patients identified as requiring surgery prior to enrollment. The study surgery is lumbar posterior fixation with supplemental posterolateral fusion at from 1 to 3 levels. One side of the posterolateral fusion will be Allosync Expand (utilizing the BMA Angel kit to hydrate) and the other side to autograft bone (control).

03

Conditions studied

  • Spondylolisthesis, Grade 1
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

A patient who meets all inclusion criteria and none exclusion criteria will be enrolled in the study. A patient is considered enrolled upon placement of the Allosync Expand during the surgical procedure. If the surgeon decides intra-operatively not to utilize Allosync Expand, the patient will be considered a screen failure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 22years of age at the time of consent
  2. Subject must have a documented diagnosis of spondylolisthesis up to Grade I. and have confirmed back and/or radicular pain with associated spinal stenosis as documented by conditions such as:

    1. Instability as defined by >3mm translation or >5 degree angulation
    2. Osteophyte formation of facet joints or vertebral endplates
  3. Subject presents with one or more of the following:

    1. Radiculopathy
    2. Sensory deficit
    3. Motor weakness
    4. Reflex changes
  4. Subject requires lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1).
  5. The number of levels decompressed must equal the number of levels fused.
  6. Subject must have been unresponsive to conservative care for at least 3 months prior to fusion surgery.
  7. Subject must be willing and able to sign an document.
  8. Subject must be willing and able to return for all follow-up visits, agree to participate in postoperative clinical and radiographic evaluations and comply with the required study regimen.

Exclusion criteria

Exclusion Criteria:

  1. Subject has had prior lumbar spine fusion surgery at any level.
  2. Subject has greater than grade 1 spondylolisthesis of the lumbar spine.
  3. Subject is pregnant or nursing or planning to become pregnant during the two years (24 months) following arthrodesis
  4. Subject has an active local or systemic infection.
  5. Subject is a prisoner
  6. Patient has any condition (including ), that in the opinion of the Investigator, would prohibit the patient from complying with and/or completing the protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Allosync Expand

    All enrolled patients will received Allosync Expand at 1-3 contiguous levels (L1-S1).

    Device: Allosync Expand

Interventions

  • DeviceAllosync Expand

    Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)

    Also known as: Acceell Family of Products (Accell DBM 100, Accell TBM, A2i, and Accell Connexus)

06

What researchers measure

Primary outcomes

  1. Lumbar fusion rate assessed via CT

    Lumbar fusion rate assessed via CT at 12 months post surgery

    Time frame: 12 months post surgery

Secondary outcomes

  1. Clinical outcome via neck visual analog scale (VAS)

    Standard of care patient reported neck visual analog scale (VAS) will be used to evaluate patient pain. On a scale of 0 to 10 with a score of 0 being no pain and a score of 10 being worst pain. A low score means a better clinical outcome. A high score means a worse clinical outcome.

    Time frame: 12 months post surgery

  2. Clinical outcome via Overall Quality of Life (EQ-5D) EuroQol Research Foundation

    Standard of care patient reported Overall Quality of Life (EQ-5D) EuroQol Research Foundation will be used to evaluate patient quality of life. On a scale of 3 levels: no problems, some problems, and extreme problems. With a score of "no problems" being no interference in quality of life and a score of "extreme problems" being a high interference in quality of life. "No problems" responses means a better clinical outcome. "Extreme problems" responses mean a worse clinical outcome.

    Time frame: 12 months post surgery

  3. Clinical outcome via PROMIS short form - Physical Evaluation

    Standard of care patient reported PROMIS short form - Physical Evaluation will be used to evaluate patient physical function. On a scale of 5 levels: without any difficulty, with a little difficulty, with some difficulty, with much difficulty, and unable to do. With a score of "without any difficulty" being no interference in physical function and a score of "unable to do" being high interference in physical function. "Without any difficulty" means a better clinical outcome. "Unable to do" means a worse clinical outcome.

    Time frame: 12 months post surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for May 2026, 23 months after the start.

Of 37 observational studies under Spondylolisthesis, half reached primary completion within 63 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 93. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 16, 2024
StartActual
Jun 5, 2024
Primary completionEst.
May 2026
CompletionEst.
May 2027
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06415110
Lead sponsor
Research Source
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Jun 5, 2024
Primary completion
May 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion